Condition: Non-Hodgkin Lymphoma · Chronic Lymphocytic Leukaemia · Multiple Myeloma · Sponsor: Bristol-Myers Squibb
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.
This description comes directly from the study's public registry record.
BMS Study Connect Contact Center www.BMSStudyConnect.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Local Institution - 0016 | Portland, Oregon, United States | Not Yet Recruiting |
| Ut Southwestern | Dallas, Texas, United States | Recruiting |
| Huntsman Cancer Institute at the University of Utah | Salt Lake City, Utah, United States | Recruiting |
| Local Institution - 0004 | Madison, Wisconsin, United States | Withdrawn |
| Universitaetsklinikum Essen (AoR) | Essen, Germany | Recruiting |
| Toyokawa City Hospital | Toyokawa, Aichi-ken, Japan | Recruiting |
| Local Institution - 0003 | Kumamoto, Kumamoto, Japan | Withdrawn |
| Kantonsspital Aarau | Aarau, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06357754